Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 273

1.

Correction to: Management of hyperglycaemia in type 2 diabetes, 2018. A consensus report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD).

Davies MJ, D'Alessio DA, Fradkin J, Kernan WN, Mathieu C, Mingrone G, Rossing P, Tsapas A, Wexler DJ, Buse JB.

Diabetologia. 2019 Mar 21. doi: 10.1007/s00125-019-4845-x. [Epub ahead of print]

PMID:
30899969
2.

Duration of Diabetes and Cardiorenal Efficacy of Liraglutide and Semaglutide: A Post Hoc Analysis of the LEADER and SUSTAIN 6 Clinical Trials.

Verma S, Bain SC, Monk Fries T, Mazer CD, Nauck MA, Pratley RE, Rasmussen S, Saevereid HA, Zinman B, Buse JB.

Diabetes Obes Metab. 2019 Mar 9. doi: 10.1111/dom.13698. [Epub ahead of print]

PMID:
30851070
3.

Cardiovascular safety and severe hypoglycaemia benefit of insulin degludec versus insulin glargine U100 in patients with type 2 diabetes aged 65 years or older: results from DEVOTE (DEVOTE 7).

Pratley RE, Emerson SS, Franek E, Gilbert MP, Marso SP, McGuire DK, Pieber TR, Zinman B, Hansen CT, Hansen MV, Mark T, Moses AC, Buse JB; DEVOTE Study Group.

Diabetes Obes Metab. 2019 Mar 8. doi: 10.1111/dom.13699. [Epub ahead of print]

PMID:
30850995
4.

Improved Time in Range and Glycemic Variability With Sotagliflozin in Combination With Insulin in Adults With Type 1 Diabetes: A Pooled Analysis of 24-Week Continuous Glucose Monitoring Data From the inTandem Program.

Danne T, Cariou B, Buse JB, Garg SK, Rosenstock J, Banks P, Kushner JA, McGuire DK, Peters AL, Sawhney S, Strumph P.

Diabetes Care. 2019 Mar 4. pii: dc182149. doi: 10.2337/dc18-2149. [Epub ahead of print]

PMID:
30833371
5.

Lower rates of cardiovascular events and mortality associated with liraglutide use in patients treated with basal insulin - A DEVOTE subanalysis (DEVOTE 10).

Brown-Frandsen K, Emerson SS, McGuire DK, Pieber TR, Poulter NR, Pratley RE, Zinman B, Ranthe MF, Grøn R, Lange M, Moses AC, Őrsy P, Buse JB; DEVOTE Study Group.

Diabetes Obes Metab. 2019 Feb 22. doi: 10.1111/dom.13677. [Epub ahead of print]

PMID:
30793465
6.

Identifying individual risk rare variants using protein structure guided local tests (POINT).

Marceau West R, Lu W, Rotroff DM, Kuenemann MA, Chang SM, Wu MC, Wagner MJ, Buse JB, Motsinger-Reif AA, Fourches D, Tzeng JY.

PLoS Comput Biol. 2019 Feb 19;15(2):e1006722. doi: 10.1371/journal.pcbi.1006722. eCollection 2019 Feb.

7.

International Consensus on Risk Management of Diabetic Ketoacidosis in Patients with Type 1 Diabetes Treated with Sodium-Glucose Cotransporter (SGLT) Inhibitors.

Danne T, Garg S, Peters AL, Buse JB, Mathieu C, Pettus JH, Alexander CM, Battelino T, Ampudia-Blasco FJ, Bode BW, Cariou B, Close KL, Dandona P, Dutta S, Ferrannini E, Fourlanos S, Grunberger G, Heller SR, Henry RR, Kurian MJ, Kushner JA, Oron T, Parkin CG, Pieber TR, Rodbard HW, Schatz D, Skyler JS, Tamborlane WV, Yokote K, Phillip M.

Diabetes Care. 2019 Feb 6. pii: dc182316. doi: 10.2337/dc18-2316. [Epub ahead of print]

PMID:
30728224
8.

Sodium-glucose co-transporter-2 inhibitor use and risk of lower-extremity amputation: Evolving questions, evolving answers.

Yang JY, Wang T, Pate V, Gower EW, Crowley MJ, Buse JB, Stürmer T.

Diabetes Obes Metab. 2019 Jan 29. doi: 10.1111/dom.13647. [Epub ahead of print]

PMID:
30697897
9.

Performance of a computable phenotype for identification of patients with diabetes within PCORnet: The Patient-Centered Clinical Research Network.

Wiese AD, Roumie CL, Buse JB, Guzman H, Bradford R, Zalimeni E, Knoepp P, Morris HL, Donahoo WT, Fanous N, Epstein BF, Katalenich BL, Ayala SG, Cook MM, Worley KJ, Bachmann KN, Grijalva CG, Rothman RL, Chakkalakal RJ.

Pharmacoepidemiol Drug Saf. 2019 Jan 24. doi: 10.1002/pds.4718. [Epub ahead of print]

PMID:
30680840
10.

Targeting hepatic glucokinase to treat diabetes with TTP399, a hepatoselective glucokinase activator.

Vella A, Freeman JLR, Dunn I, Keller K, Buse JB, Valcarce C.

Sci Transl Med. 2019 Jan 16;11(475). pii: eaau3441. doi: 10.1126/scitranslmed.aau3441.

PMID:
30651321
11.

Effects of Liraglutide on Cardiovascular Outcomes in Patients With Type 2 Diabetes Mellitus With or Without History of Myocardial Infarction or Stroke.

Verma S, Poulter NR, Bhatt DL, Bain SC, Buse JB, Leiter LA, Nauck MA, Pratley RE, Zinman B, Ørsted DD, Monk Fries T, Rasmussen S, Marso SP.

Circulation. 2018 Dec 18;138(25):2884-2894. doi: 10.1161/CIRCULATIONAHA.118.034516.

PMID:
30566004
12.

Assessing the Association Between GLP-1 Receptor Agonist Use and Diabetic Retinopathy Through the FDA Adverse Event Reporting System.

Wang T, Lu W, Tang H, Buse JB, Stürmer T, Gower EW.

Diabetes Care. 2019 Feb;42(2):e21-e23. doi: 10.2337/dc18-1893. Epub 2018 Dec 7. No abstract available.

PMID:
30530488
13.

Advances in transdermal insulin delivery.

Zhang Y, Yu J, Kahkoska AR, Wang J, Buse JB, Gu Z.

Adv Drug Deliv Rev. 2018 Dec 8. pii: S0169-409X(18)30309-0. doi: 10.1016/j.addr.2018.12.006. [Epub ahead of print] Review.

PMID:
30528729
14.

Effect of Liraglutide on Cardiovascular Outcomes in Elderly Patients: A Post Hoc Analysis of a Randomized Controlled Trial.

Gilbert MP, Bain SC, Franek E, Jodar-Gimeno E, Nauck MA, Pratley R, Réa RR, Kerr Saraiva JF, Rasmussen S, Tornøe K, von Scholten BJ, Buse JB; and the LEADER Publication Committee on behalf of the LEADER Trial Investigators.

Ann Intern Med. 2018 Dec 4. doi: 10.7326/M18-1569. [Epub ahead of print] No abstract available.

PMID:
30508430
15.

Health Literacy, Glycemic Control, and Physician-Advised Glucose Self-Monitoring Use in Type 2 Diabetes.

Alvarez PM, Young LA, Mitchell M, Blakeney TG, Buse JB, Vu MB, Weaver MA, Rees J, Grimm K, Donahue KE.

Diabetes Spectr. 2018 Nov;31(4):344-347. doi: 10.2337/ds18-0064.

PMID:
30510390
16.

Impact of metformin use on the cardiovascular effects of dipeptidyl peptidase-4 inhibitors: An analysis of Medicare claims data from 2007 to 2015.

Crowley MJ, Gokhale M, Pate V, Stürmer T, Buse JB.

Diabetes Obes Metab. 2018 Nov 20. doi: 10.1111/dom.13589. [Epub ahead of print]

PMID:
30456843
17.

Liraglutide and Glycaemic Outcomes in the LEADER Trial.

Zinman B, Nauck MA, Bosch-Traberg H, Frimer-Larsen H, Ørsted DD, Buse JB; LEADER Publication Committee on behalf of the LEADER Trial Investigators.

Diabetes Ther. 2018 Dec;9(6):2383-2392. doi: 10.1007/s13300-018-0524-z. Epub 2018 Nov 3.

18.

Effect of Once-Weekly Exenatide on Clinical Outcomes According to Baseline Risk in Patients With Type 2 Diabetes Mellitus: Insights From the EXSCEL Trial.

Mentz RJ, Bethel MA, Merrill P, Lokhnygina Y, Buse JB, Chan JC, Felício JS, Goodman SG, Choi J, Gustavson SM, Iqbal N, Lopes RD, Maggioni AP, Öhman P, Pagidipati NJ, Poulter NR, Ramachandran A, Reicher B, Holman RR, Hernandez AF; EXSCEL Study Group.

J Am Heart Assoc. 2018 Oct 2;7(19):e009304. doi: 10.1161/JAHA.118.009304.

19.

Long-Term Effects of Intensive Glycemic and Blood Pressure Control and Fenofibrate Use on Kidney Outcomes.

Mottl AK, Buse JB, Ismail-Beigi F, Sigal RJ, Pedley CF, Papademetriou V, Simmons DL, Katz L, Mychaleckyj JC, Craven TE.

Clin J Am Soc Nephrol. 2018 Nov 7;13(11):1693-1702. doi: 10.2215/CJN.06200518. Epub 2018 Oct 25.

PMID:
30361335
20.

Management of Hyperglycemia in Type 2 Diabetes, 2018. A Consensus Report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD).

Davies MJ, D'Alessio DA, Fradkin J, Kernan WN, Mathieu C, Mingrone G, Rossing P, Tsapas A, Wexler DJ, Buse JB.

Diabetes Care. 2018 Dec;41(12):2669-2701. doi: 10.2337/dci18-0033. Epub 2018 Oct 4.

PMID:
30291106
21.

Management of hyperglycaemia in type 2 diabetes, 2018. A consensus report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD).

Davies MJ, D'Alessio DA, Fradkin J, Kernan WN, Mathieu C, Mingrone G, Rossing P, Tsapas A, Wexler DJ, Buse JB.

Diabetologia. 2018 Dec;61(12):2461-2498. doi: 10.1007/s00125-018-4729-5. Erratum in: Diabetologia. 2019 Mar 21;:.

PMID:
30288571
22.

Genetic Tools for Coronary Risk Assessment in Type 2 Diabetes: A Cohort Study From the ACCORD Clinical Trial.

Morieri ML, Gao H, Pigeyre M, Shah HS, Sjaarda J, Mendonca C, Hastings T, Buranasupkajorn P, Motsinger-Reif AA, Rotroff DM, Sigal RJ, Marcovina SM, Kraft P, Buse JB, Wagner MJ, Gerstein HC, Mychaleckyj JC, Parè G, Doria A.

Diabetes Care. 2018 Nov;41(11):2404-2413. doi: 10.2337/dc18-0709. Epub 2018 Sep 27.

PMID:
30262460
23.

Health-related quality of life in people with type 2 diabetes participating in the LEADER trial.

Nauck MA, Buse JB, Mann JFE, Pocock S, Bosch-Traberg H, Frimer-Larsen H, Ye Q, Gray A; LEADER Publication Committee for the LEADER Trial Investigators.

Diabetes Obes Metab. 2019 Mar;21(3):525-532. doi: 10.1111/dom.13547. Epub 2018 Oct 25.

24.

Fast-acting insulin aspart versus insulin aspart in the setting of insulin degludec-treated type 1 diabetes: Efficacy and safety from a randomized double-blind trial.

Buse JB, Carlson AL, Komatsu M, Mosenzon O, Rose L, Liang B, Buchholtz K, Horio H, Kadowaki T.

Diabetes Obes Metab. 2018 Dec;20(12):2885-2893. doi: 10.1111/dom.13545. Epub 2018 Oct 10.

25.

Strategy for Mitigating DKA Risk in Patients with Type 1 Diabetes on Adjunctive Treatment with SGLT Inhibitors: A STICH Protocol.

Garg SK, Peters AL, Buse JB, Danne T.

Diabetes Technol Ther. 2018 Sep;20(9):571-575. doi: 10.1089/dia.2018.0246. Epub 2018 Aug 21. No abstract available.

PMID:
30129772
26.

The Impact of Liraglutide on Diabetes-Related Foot Ulceration and Associated Complications in Patients With Type 2 Diabetes at High Risk for Cardiovascular Events: Results From the LEADER Trial.

Dhatariya K, Bain SC, Buse JB, Simpson R, Tarnow L, Kaltoft MS, Stellfeld M, Tornøe K, Pratley RE; LEADER Publication Committee on behalf of the LEADER Trial Investigators.

Diabetes Care. 2018 Oct;41(10):2229-2235. doi: 10.2337/dc18-1094. Epub 2018 Aug 2.

PMID:
30072400
27.

Management of Type 1 Diabetes With a Very Low-Carbohydrate Diet: A Word of Caution.

Mayer-Davis EJ, Laffel LM, Buse JB.

Pediatrics. 2018 Aug;142(2). pii: e20181536B. doi: 10.1542/peds.2018-1536B. No abstract available.

PMID:
30065007
28.

Implementation and Evaluation of Shared Medical Appointments for Type 2 Diabetes at a Free, Student-Run Clinic in Alamance County, North Carolina.

Kahkoska AR, Brazeau NF, Lynch KA, Kirkman MS, Largay J, Young LA, Buse JB.

J Med Educ Train. 2018;2(1). pii: 032.

29.

Primum Non Nocere: Refocusing Our Attention on Severe Hypoglycemia Prevention.

Kahkoska AR, Buse JB.

Diabetes Care. 2018 Aug;41(8):1557-1559. doi: 10.2337/dci18-0020. No abstract available.

PMID:
30030257
30.

Incretin-Based Therapies and Diabetic Retinopathy: Real-World Evidence in Older U.S. Adults.

Wang T, Hong JL, Gower EW, Pate V, Garg S, Buse JB, Stürmer T.

Diabetes Care. 2018 Sep;41(9):1998-2009. doi: 10.2337/dc17-2285. Epub 2018 Jul 16.

PMID:
30012674
31.

Calendar time as an instrumental variable in assessing the risk of heart failure with antihyperglycemic drugs.

Gokhale M, Buse JB, DeFilippo Mack C, Jonsson Funk M, Lund J, Simpson RJ, Stürmer T.

Pharmacoepidemiol Drug Saf. 2018 Aug;27(8):857-866. doi: 10.1002/pds.4578. Epub 2018 Jun 26.

PMID:
29943442
32.

Can We RISE to the Challenge of Youth-Onset Type 2 Diabetes?

Buse JB, D'Alessio DA, Riddle MC.

Diabetes Care. 2018 Aug;41(8):1560-1562. doi: 10.2337/dci18-0025. Epub 2018 Jun 25. No abstract available.

PMID:
29941499
33.
34.

Sotagliflozin in Combination With Optimized Insulin Therapy in Adults With Type 1 Diabetes: The North American inTandem1 Study.

Buse JB, Garg SK, Rosenstock J, Bailey TS, Banks P, Bode BW, Danne T, Kushner JA, Lane WS, Lapuerta P, McGuire DK, Peters AL, Reed J, Sawhney S, Strumph P.

Diabetes Care. 2018 Sep;41(9):1970-1980. doi: 10.2337/dc18-0343. Epub 2018 Jun 24.

PMID:
29937430
35.

Hypoglycemia, Cardiovascular Outcomes, and Death: The LEADER Experience.

Zinman B, Marso SP, Christiansen E, Calanna S, Rasmussen S, Buse JB; LEADER Publication Committee on behalf of the LEADER Trial Investigators.

Diabetes Care. 2018 Aug;41(8):1783-1791. doi: 10.2337/dc17-2677. Epub 2018 Jun 14.

PMID:
29903847
36.

Adiponectin, Free Fatty Acids, and Cardiovascular Outcomes in Patients With Type 2 Diabetes and Acute Coronary Syndrome.

Schrieks IC, Nozza A, Stähli BE, Buse JB, Henry RR, Malmberg K, Neal B, Nicholls SJ, Rydén L, Mellbin L, Svensson A, Wedel H, Weichert A, Lincoff AM, Tardif JC, Grobbee DE, Schwartz GG.

Diabetes Care. 2018 Aug;41(8):1792-1800. doi: 10.2337/dc18-0158. Epub 2018 Jun 14.

37.

Neoplasms Reported With Liraglutide or Placebo in People With Type 2 Diabetes: Results From the LEADER Randomized Trial.

Nauck MA, Jensen TJ, Rosenkilde C, Calanna S, Buse JB; LEADER Publication Committee on behalf of the LEADER Trial Investigators.

Diabetes Care. 2018 Aug;41(8):1663-1671. doi: 10.2337/dc17-1825. Epub 2018 Jun 13.

PMID:
29898902
38.

Efficacy and safety of dapagliflozin in patients with type 2 diabetes and moderate renal impairment (chronic kidney disease stage 3A): The DERIVE Study.

Fioretto P, Del Prato S, Buse JB, Goldenberg R, Giorgino F, Reyner D, Langkilde AM, Sjöström CD, Sartipy P; DERIVE Study Investigators.

Diabetes Obes Metab. 2018 Nov;20(11):2532-2540. doi: 10.1111/dom.13413. Epub 2018 Jul 10. Erratum in: Diabetes Obes Metab. 2019 Jan;21(1):203.

39.

Effect of Liraglutide on Cardiovascular Events in Patients With Type 2 Diabetes Mellitus and Polyvascular Disease: Results of the LEADER Trial.

Verma S, Bhatt DL, Bain SC, Buse JB, Mann JFE, Marso SP, Nauck MA, Poulter NR, Pratley RE, Zinman B, Michelsen MM, Monk Fries T, Rasmussen S, Leiter LA; LEADER Publication Committee on behalf of the LEADER Trial Investigators.

Circulation. 2018 May 15;137(20):2179-2183. doi: 10.1161/CIRCULATIONAHA.118.033898. No abstract available.

40.

DEVOTE 5: Evaluating the Short-Term Cost-Utility of Insulin Degludec Versus Insulin Glargine U100 in Basal-Bolus Regimens for Type 2 Diabetes in the UK.

Pollock RF, Valentine WJ, Marso SP, Gundgaard J, Hallén N, Hansen LL, Tutkunkardas D, Buse JB; DEVOTE Study Group.

Diabetes Ther. 2018 Jun;9(3):1217-1232. doi: 10.1007/s13300-018-0430-4. Epub 2018 Apr 30.

41.

Homeostasis Model Assessment of Insulin Resistance and Survival in Patients With Diabetes and Acute Coronary Syndrome.

Stähli BE, Nozza A, Schrieks IC, Buse JB, Malmberg K, Mellbin L, Neal B, Nicholls SJ, Rydén L, Svensson A, Wedel H, Weichert A, Lincoff AM, Grobbee DE, Tardif JC, Schwartz GG.

J Clin Endocrinol Metab. 2018 Jul 1;103(7):2522-2533. doi: 10.1210/jc.2017-02772.

PMID:
29659887
42.

A survey of practices for the use of electronic health records to support research recruitment.

Obeid JS, Beskow LM, Rape M, Gouripeddi R, Black RA, Cimino JJ, Embi PJ, Weng C, Marnocha R, Buse JB.

J Clin Transl Sci. 2017 Aug;1(4):246-252. doi: 10.1017/cts.2017.301.

43.

Genetic Variants in CPA6 and PRPF31 Are Associated With Variation in Response to Metformin in Individuals With Type 2 Diabetes.

Rotroff DM, Yee SW, Zhou K, Marvel SW, Shah HS, Jack JR, Havener TM, Hedderson MM, Kubo M, Herman MA, Gao H, Mychaleckyi JC, McLeod HL, Doria A, Giacomini KM, Pearson ER, Wagner MJ, Buse JB, Motsinger-Reif AA; MetGen Investigators; ACCORD/ACCORDion Investigators.

Diabetes. 2018 Jul;67(7):1428-1440. doi: 10.2337/db17-1164. Epub 2018 Apr 12.

44.

Myocardial Infarction Subtypes in Patients With Type 2 Diabetes Mellitus and the Effect of Liraglutide Therapy (from the LEADER Trial).

Marso SP, Nauck MA, Monk Fries T, Rasmussen S, Treppendahl MB, Buse JB; LEADER Publication Committee on behalf of the LEADER Trial Investigators.

Am J Cardiol. 2018 Jun 15;121(12):1467-1470. doi: 10.1016/j.amjcard.2018.02.030. Epub 2018 Mar 15.

45.

The Risk of Acute Pancreatitis After Initiation of Dipeptidyl Peptidase 4 Inhibitors: Testing a Hypothesis of Subgroup Differences in Older U.S. Adults.

Hong JL, Buse JB, Jonsson Funk M, Pate V, Stürmer T.

Diabetes Care. 2018 Jun;41(6):1196-1203. doi: 10.2337/dc17-2212. Epub 2018 Apr 4.

PMID:
29618573
46.

Longitudinal medical resources and costs among type 2 diabetes patients participating in the Trial Evaluating Cardiovascular Outcomes with Sitagliptin (TECOS).

Reed SD, Li Y, Leal J, Radican L, Adler AI, Alfredsson J, Buse JB, Green JB, Kaufman KD, Riefflin A, Van de Werf F, Peterson ED, Gray AM, Holman RR; TECOS Study Group.

Diabetes Obes Metab. 2018 Jul;20(7):1732-1739. doi: 10.1111/dom.13292. Epub 2018 Apr 20.

PMID:
29573215
47.

Bioresponsive Microneedles with a Sheath Structure for H2 O2 and pH Cascade-Triggered Insulin Delivery.

Zhang Y, Wang J, Yu J, Wen D, Kahkoska AR, Lu Y, Zhang X, Buse JB, Gu Z.

Small. 2018 Apr;14(14):e1704181. doi: 10.1002/smll.201704181. Epub 2018 Feb 26.

48.

Core-Shell Microneedle Gel for Self-Regulated Insulin Delivery.

Wang J, Ye Y, Yu J, Kahkoska AR, Zhang X, Wang C, Sun W, Corder RD, Chen Z, Khan SA, Buse JB, Gu Z.

ACS Nano. 2018 Mar 27;12(3):2466-2473. doi: 10.1021/acsnano.7b08152. Epub 2018 Feb 19.

49.

Increased Risk of Severe Hypoglycemic Events Before and After Cardiovascular Outcomes in TECOS Suggests an At-Risk Type 2 Diabetes Frail Patient Phenotype.

Standl E, Stevens SR, Armstrong PW, Buse JB, Chan JCN, Green JB, Lachin JM, Scheen A, Travert F, Van de Werf F, Peterson ED, Holman RR; TECOS Study Group.

Diabetes Care. 2018 Mar;41(3):596-603. doi: 10.2337/dc17-1778. Epub 2018 Jan 8.

PMID:
29311155
50.

Cardiovascular Outcomes Trials in Type 2 Diabetes: Where Do We Go From Here? Reflections From a Diabetes Care Editors' Expert Forum.

Cefalu WT, Kaul S, Gerstein HC, Holman RR, Zinman B, Skyler JS, Green JB, Buse JB, Inzucchi SE, Leiter LA, Raz I, Rosenstock J, Riddle MC.

Diabetes Care. 2018 Jan;41(1):14-31. doi: 10.2337/dci17-0057.

Supplemental Content

Support Center